Amisha Rastogi

Amisha Rastogi

Auto-generated profile, based on publicly available information

Amisha Rastogi

Department of Biotechnology, GLA University, Mathura, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ABAlok Bhardwaj
Alok Bhardwaj
ARAmisha Rastogi
Amisha Rastogi
SPSwadha Pandey
Swadha Pandey
Saurabh GuptaSaurabh Gupta
Saurabh Gupta
JSJagdip Singh Sohal
Jagdip Singh Sohal
In the present scenario, resistance to antibiotics is one of the crucial issues related to public health. Earlier, such resistance to antibiotics was limited to nosocomial infections, but it has now become a common phenomenon. Several factors, like extensive development, overexploitation of antibiotics, excessive application of broad‐spectrum drugs, and a shortage of target‐oriented antimicrobial drugs, could be attributed to this condition. Nowadays, there is a rise in the occurrence of these drug‐resistant pathogens due to the availability of a small number of effective antimicrobial agents. It has been estimated that if new novel drugs are not discovered or formulated, there would be no effective antibiotic available to treat these deadly resistant pathogens by 2050. For this reason, we have to look for the formulation of some new novel drugs or other options or substitutes to treat such multidrug‐resistant microorganisms (MDR). The current review focuses on the evolution of the most common multidrug‐resistant bacteria and discusses how these bacteria escape the effects of targeted antibiotics and become multidrug resistant. In addition, we also discuss some alternative mechanisms to prevent their infection as well.

1 December 2024 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAnjana Goel
Anjana Goel
ARAmisha Rastogi
Amisha Rastogi
MJMansi Jain
Mansi Jain
KNKinjal Niveriya
Kinjal Niveriya
: It is becoming more and harder in today's climate to disregard the impact of cancer on social health. Even though a significant amount of money is spent annually on cancer research, it still ranks as the second leading cause of death worldwide. Additionally, only about half of the patients suffering from complex forms of cancer survive a year after receiving traditional cancer therapies. A method for silencing genes is called RNA interference (RNAi). Such a method is very effective in focusing on genes linked to cancer. Most gene products implicated in cancer have recently been used as RNA interference (RNAi) therapeutic targets. According to the findings from this research, RNAi application is necessary for today's cancer treatment to target functioning carcinogenic molecules and tumor resistance to chemotherapy and radiation. Proapoptotic and antiproliferative activity has been reported from previous research studies on cell culture systems, animal models, and clinical trials through the knockdown of gene products from RNAi technology. Numerous novel RNAi-based medications are now in the clinical trial stages thanks to the discovery of the RNAi mechanism and advancements in the area. In the future, genomic-based personalized medicines can be developed through this RNAi therapy. Hopefully, cancer sufferers will find this sort of therapy to be one of the most effective ones. Various kinds of RNA-based treatments, such as aptamers, small interfering RNAs, microRNAs, antisense oligonucleotides, and messenger RNA, are covered in broad terms in this study. We also present an overview of the RNA-based therapies that have received regulatory approval in the past or are now undergoing clinical studies.